Skip to content
CancerIndex

Publication

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.

Authors not recorded

Br J Cancer1998PMID 9569050PMC2150115stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

Curated evidence

Evidence citing this paper (5)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
9569050
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
TP53 Mutation1
(prognostic)Malignant Breast NeoplasmPrognosticBSupports Poor Outcome3accepted
EID393

In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53. Multivariate Cox … (full text at CIViC)

PMID 9569050 · Berns et al., 1998 · Open in CIViC

civic
TP53 R248Q1
(prognostic)Malignant Breast NeoplasmPrognosticBSupports Poor Outcome3accepted
EID391

In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 (N=10, 6 at R248) are prognostic for a worse relapse-free survival compared to other non-silent mutatio… (full text at CIViC)

PMID 9569050 · Berns et al., 1998 · Open in CIViC

civic
TP53 R2491
DoxorubicinMalignant Breast NeoplasmPredictiveBSupports Sensitivity Response3accepted
EID399

Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.

PMID 9569050 · Berns et al., 1998 · Open in CIViC

civic
TP53 R273C1
(prognostic)Malignant Breast NeoplasmPrognosticBSupports Poor Outcome3accepted
EID396

In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.

PMID 9569050 · Berns et al., 1998 · Open in CIViC

civic
TP53 R273H1
(prognostic)Malignant Breast NeoplasmPrognosticBSupports Poor Outcome3accepted
EID398

In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53.

PMID 9569050 · Berns et al., 1998 · Open in CIViC

civic